ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNN Smith and Nephew Plc New

30.80
0.29 (0.95%)
After Hours
Last Updated: 22:32:38
Delayed by 15 minutes
Name Symbol Market Type
Smith and Nephew Plc New NYSE:SNN NYSE Depository Receipt
  Price Change % Change Price High Price Low Price Open Price Traded Last Trade
  0.29 0.95% 30.80 30.87 30.39 30.39 1,479,990 22:32:38

Medical-Device Maker Zimmer Narrows Revenue Projection

24/06/2015 7:26pm

Dow Jones News


Smith and Nephew (NYSE:SNN)
Historical Stock Chart


From Sep 2019 to Sep 2024

Click Here for more Smith and Nephew Charts.
By Maria Armental 

Zimmer Holdings Inc. on Wednesday narrowed its revenue projection for the year as it sold several assets in order to complete the acquisition of Biomet in a deal valued at $14 billion.

As part of the deal, Zimmer sold a knee replacement system in the U.S. to British medical technology business Smith & Nephew PLC and elbow implant and cobalt bone cement rights and assets to California-based DJO Global Inc. to resolve regulatory competition issues.

Zimmer and Biomet are two of the only three substantial competitors in the U.S. for unicondylar knee implants and total elbow implants, and two of only four significant competitors for bone cement, the Federal Trade Commission had said.

The deal with Smith & Nephew is set to close within three days. Financial terms weren't disclosed.

The Indiana company will be renamed Zimmer Biomet Holdings Inc. and will trade in the U.S. and Switzerland under the ticker symbol ZBH starting June 29. The combined company's board has been increased to 12 members, including Michael W. Michelson of private-equity firm KKR & Co. and Jeffrey K. Rhodes of TPG Capital.

Zimmer Biomet said it now projects revenue, including Biomet revenue for the comparable period less the assets sold, to increase 1.5% to 2%, compared with its previous view of 1.5% to 2.5%.

For the current quarter, Zimmer Biomet projects profit of $1.55 to $1.58 a share, compared with the consensus of $1.55 a share, according to Thomson Reuters.

The company will release its second-quarter results on July 30.

Shares rose 1.1% to $113.89 in early afternoon trading.

Write to Maria Armental at maria.armental@wsj.com

Access Investor Kit for Smith & Nephew Plc

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=GB0009223206

Access Investor Kit for Smith & Nephew Plc

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US83175M2052

Access Investor Kit for Zimmer Holdings, Inc.

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US98956P1021

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Smith and Nephew Chart

1 Year Smith and Nephew Chart

1 Month Smith and Nephew Chart

1 Month Smith and Nephew Chart